FrancophonIA/ELRC3.0 huggingface dataset:
English: As with other cytotoxic medicinal products, topotecan may cause foetal harm and therefore women of childbearing potential should be advised to avoid becoming pregnant during therapy with topotecan.
Danish: Som for andre cytostatika kan topotecan forårsage fosterskader, hvorfor kvinder i den fertile alder bør tilrådes at undgå graviditet, hvis de er i behandling med topotecan.
English: If either cisplatin or carboplatin is given on day 1 of the topotecan dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each agent which can be given if the platinum agent is given on day 5 of the topotecan dosing.
Danish: Hvis enten cisplatin eller carboplatin gives på dag 1 for topotecan doseringen, skal der gives en lavere dosis af begge stoffer, for at forbedre tolerancen, i forhold til den indivudielle dosis der kan gives af platin stofferne, hvis de gives på dag 5 for topotecan doseringen.
English: Potactasol may cause a decrease in the number of blood clotting cells (platelets).
Danish: Potactasol kan nedsætte antallet af blodceller (blodplader).
English: Effective contraception methods should be used to avoid becoming pregnant or fathering a child while on treatment with Potactasol.
Danish: Du skal anvende effektive præventionsmetoder under behandlingen med Potactasol for at undgå at blive gravid eller blive far til et barn.
English: The prescribing information for cisplatin should be consulted for a full list of adverse events associated with cisplatin use.
Danish: Cisplatin produktinformation bør konsulteres for en komplet liste over bivirkninger associeret til brugen af cisplatin.
English: In a population study using the intravenous route, the co-administration of granisetron, ondansetron, morphine or corticosteroids did not appear to have a significant effect on the pharmacokinetics of total topotecan (active and inactive form).
Danish: I et populationsstudie med intravenøs administration havde samtidig administration af granisetron, ondansetron, morphin eller kortikosteroider, ingen signifikant virkning på farmakokinetikken af total topotecan (aktiv og inaktiv form).
English: The unadjusted hazard ratio for the oral topotecan plus BSC group relative to the BSC alone group was 0.64 (95 % CI: 0.45, 0.90).
Danish: Den ikke-justerede hazard ratio for oral topotecan plus BSC-gruppen i forhold til gruppen med BSC alene var 0,64 (95 % CI; 0,45; 0,90).
English: However, when combining with platinum agents, there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on day 1 or 5 of the topotecan dosing.
Danish: Ved kombination med platin-baseret kemoterapi er der dog en særlig sekvens-afhængig interaktion, afhængig af om platin stoffet gives på dag 1 eller 5 i forhold til topotecan doseringen.
English: In the event of contact with the eyes, irrigate with large amounts of water.
Danish: Hvis det kommer i kontakt med øjnene, skylles der med rigelige mængder vand.
English: The response rate to topotecan in the combined small cell lung cancer programme (n = 480) for patients with relapsed disease sensitive to first-line therapy, was 20.2 %.
Danish: Responsraten for topotecan i det kombinerede program for småcellet lungecancer [n = 480] for patienter med recidiverende sygdom efter førstebehandling var 20,2 %.
English: Potactasol contains the active substance topotecan which helps to kill tumour cells.
Danish: Potactasol indeholder det aktive stof topotekan, som hjælper til med at ødelægge kræftceller.
English: Do not use this medicine after the expiry date which is stated on the vial and carton after EXP.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på hætteglasset og pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
English: Talk to your doctor before using Potactasol: - if you have any kidney problems.
Danish: Kontakt lægen, før du får Potactasol hvis du har nyreproblemer.
English: - Allergic (hypersensitivity) reactions (including rash).
Danish: - Allergi eller overfølsomhedsreaktioner (herunder udvikling af udslæt)
English: The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Danish: Anti-tumor aktiviteten af topotecan involverer hæmning af topoisomerase-I, et enzym tæt involveret i DNA replikation, da den eliminerer det torsionale belastning, der opstår foran den bevægelige replikationsgaffel.
English: Haematological toxicity is dose-related and full blood count including platelets should be determined regularly (see section 4.2).
Danish: Den hæmatologiske toksicitet er dosisafhængig, og det samlede blodbillede, herunder trombocytter, bør fastlægges jævnligt (se pkt.
English: Based on the dose-limiting toxicity of myelosuppression, the maximum tolerated dose (MTD) was established at 2.0 mg/m2/day with G-CSF and 1.4 mg/m2/day without G-CSF in a pharmacokinetic study in paediatric patients with refractory solid tumours (see section 5.2).
Danish: På baggrund af den toksiske grænseværdi for myelosuppression blev den maximalt tolererede dosis (MTD) fastsat til 2,0 mg/m2/dag med G-CSF og 1,4 mg/m2/dag uden GCSF i et farmakokinetisk studie hos børn med refraktære solide tumorer (se pkt.
English: - Infections (very common; may affect more than 1 in 10 people), with signs such as: - fever - serious decline of your general condition - local symptoms, such as sore throat or burning sensation when urinating - severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel inflammation (neutropenic colitis) Potactasol may reduce your ability to fight infections.
Danish: - Infektioner (meget almindelig, kan ske hos flere end 1 ud af 10 personer), med symptomer som: - feber - alvorlig forværrelse af din generelle tilstand - lokale symptomer så som halssmerter eller en brændende følelse, når du tisser - stærke mavesmerter, feber og muligvis diare (sjældent med blod) kan være tegn på tyktarmsbetændelse (neutropenisk colitis).
English: Reykjavíkurvegi 76-78 220 Hafnarfjörður Iceland
Danish: Reykjavikurvegi 76-78 220 Hafnarfjordur Island
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Danish: Hvis det ikke anvendes omgående, er ansvaret for i-brug-tid og opbevaringsbetingelser forud for anvendelse brugers og vil normalt ikke være længere end 24 timer ved 2 til 8 °C, medmindre rekonstituering/fortynding er foretaget under kontrollerede og validerede aseptiske forhold.
English: If, during topotecan/cisplatin combination therapy serum creatinine exceeds 1.5 mg/dl, it is recommended that the full prescribing information be consulted for any advice on cisplatin dose reduction/continuation.
Danish: Hvis serumkreatinin under kombinationsbehandling overstiger 1,5 mg/dl anbefales det at konsultere cisplatin produktinformation vedrørende dosisreduktion/fortsat behandling.
English: Topotecan monotherapy and topotecan in combination with cisplatin are commonly associated with clinically relevant thrombocytopenia.
Danish: Topotecan monoterapi og topotecan i kombination med cisplatin, er sædvanligvis associeret med klinisk relevant trombocytopeni.
English: A Phase III study (Study 478) compared oral topotecan plus best supportive care (BSC) (n = 71) with BSC alone (n = 70) in patients who had relapsed following first line therapy (median time to progression [TTP] from first-line therapy: 84 days for oral topotecan plus BSC, 90 days for BSC alone) and for whom re-treatment with intravenous chemotherapy was not considered appropriate.
Danish: I en fase III-studie (studie 478) blev oral topotecan plus best supportive care (BSC)(n = 71) sammenlignet med BSC alene (n = 70) hos patienter, som havde tilbagefald efter 1.linje-behandling (mediantid til progression [TTP] fra 1. linje-behandling: 84 dage for oral topotecan plus BSC, 90 dage for BSC alene) og for hvem gentagelse af behandling med i.v.
English: The hazard ratio for survival with IV topotecan relative to CAV was 1.04 (95 %, CI 0.78 -1.40).
Danish: Hazard ratio for overlevelse med intravenøs topotecan relativt til CAV var 1,04 (95 % CI 0,78; 1,40).
English: − Personnel should be trained to reconstitute and dilute the the medicinal product.
Danish: • Personalet skal være uddannet i at rekonstituere og fortynde lægemidlet.
English: The normal procedures for proper handling and disposal of anti-tumour medicinal products should be adopted:
Danish: De normale procedurer for omgang med anti-tumor medicin skal følges:
English: - if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section 6); - if you are breast-feeding.
Danish: - hvis du er allergisk over for topotecan eller et af de øvrige indholdsstoffer i Potactasol (angivet i afsnit 6 )
English: This should be taken into account, when prescribing topotecan, e.g. if patients at increased risk of tumour bleeds are considered for therapy.
Danish: Dette bør overvejes når Potactasol ordineres f.eks. i tilfælde, hvor det overvejes at behandle patienter med øget risiko for tumorblødning.
English: Cisplatin 50 mg/m2 on day 1, + Topotecan 0,75 mg/m2 on days 1-3, every 21 days
Danish: Cisplatin 50 mg/m2 på dag 1 + Topotecan 0,75 mg/m2 på dag 1-3, hver 21. dag
English: Other medicines and Potactasol
Danish: Brug af anden medicin sammen med Potactasol
English: Infections and infestations Very common:
Danish: Infektioner og parasitære sygdomme Meget almindelig: infektion Almindelig:
English: - Severe allergic (anaphylactic) reactions (rare; may affect up to 1 in 1,000 people), with signs such as: - swelling of the face, lips, tongue or throat, difficulty breathing, low blood pressure, dizziness and itchy rash.
Danish: Alvorlige allergiske (anafylaktiske) reaktioner (sjælden, kan påvireke op til 1 ud af 1.000 personer) med symptomer som f.eks.: - hævelse i ansigtet, læberne, tungen eller halsen, vejtrækningsbesvær, lavt blodtryk, svimmelhed og kløende udslæt.
English: − Personnel handling this medicinal product during reconstitution and dilution should wear protective clothing including mask, goggles and gloves.
Danish: − Personale, som håndterer dette medikament under rekonstitution og fortynding skal bære beskyttelsesdragt, herunder maske, beskyttelsesbriller og handsker.
English: The mean metabolite:parent AUC ratio was < 10 % for both total topotecan and topotecan lactone.
Danish: Det gennemsnitlige forhold mellem hovedmetabolitten og lægemiddelstoffets AUC var < 10 % for såvel topotecan som topotecanlaketon.
English: When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m2 compared to 21.3 l/h/m2 [n = 9]) (see section 4.5).
Danish: Ved administration i kombination med cisplatin (cisplatin dag 1, topotecan dag 1 til 5) blev topotecanclearance reduceret på dag 5 sammenlignet med dag 1 (19,1 l/time/m2 legemsoverflade sammenlignet med 21,3 l/h/ m2 legemsoverflade [n = 9]) (se pkt.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Danish: Du kan finde yderligere information om Potactasol på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http://www.ema.europa.eu/.
English: The recommended monotherapy dose of topotecan in patients with ovarian or small cell lung carcinoma and a creatinine clearance between 20 and 39 ml/min is 0.75 mg/m2/day for five consecutive days.
Danish: Den rekommanderede topotecandosis ved monoterapi hos patienter med ovariecancer og småcellet lungecancer og en kreatinin clearance mellem 20 og 39 ml/min er 0,75 mg/m2/dag i fem sammenhængende dage.
English: Plasma clearance in patients with hepatic impairment (serum bilirubin between 1.5 and 10 mg/dl) decreased to about 67 % when compared with a control group of patients.
Danish: Plasmaclearance hos patienter med nedsat leverfunktion (serum bilirubin mellem 1,5 og 10 mg/dl) faldt til ca. 67 % sammenlignet med en kontrolgruppe af patienter.
English: In another randomised Phase III study which compared intravenous (IV) topotecan to cyclophosphamide, doxorubicin and vincristine (CAV) in patients with relapsed, sensitive SCLC, the overall response rate was 24.3 % for topotecan compared to 18.3 % for the CAV group.
Danish: topotecan med cyclophosphamid, doxorubicin og vincristin (CAV) hos patienter med recidiverende, sensitiv SCLC, var den samlede responsrate 24,3 % for topotecan sammenlignet med 18,3 % for CAV gruppen.
English: The usual dose is 1.5 mg per m2 of body surface area once daily for 5 days.
Danish: Den sædvanlige dosis er: 1,5 mg/m2 af kroppens overfladeareal en gang om dagen i 5 dage.
English: In association with severe neutropenia, fever or infection occurred in 16 % of patients during course 1 and overall in 23 %
Danish: I forbindelse med alvorlig neutropeni forekom feber eller infektion hos 16 % af patienterne under serie 1 og totalt set hos 23 % af patienterne (6 % af serierne).
English: - The active substance is topotecan.
Danish: Aktivt stof: topotecan.
English: Any unused product or waste material should be disposed of in accordance with local requirements.
Danish: Ubrugt eller overskud af lægemiddel skal bortskaffes i henhold til lokale bestemmelser.
English: Tell your doctor if you are taking, have recently taken or might take any other medicines.
Danish: Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin eller har brugt det for nylig.
English: Patients with impaired kidney function Your doctor might need to reduce your dose based on your kidney function.
Danish: Patienter med nedsat nyrefunktion Afhængigt af din nyrefunktion vil lægen eventuelt nedsætte din dosis.
English: Potactasol is for intravenous infusion after reconstitution and dilution.
Danish: Potactasol er til til intravenøs infusion efter rekonstitution og fortynding.
English: In an open-label study involving children (n = 108, age range: infant to 16 years) with recurrent or progressive solid tumours, topotecan was administered at a starting dose of 2.0 mg/m2 given as a
Danish: I et ikke blindet studie af børn (n = 108; aldersgruppe: børn op til 16 år) med recidiverende eller progredierende solide tumorer, blev topotecan administreret med en startdosis på 2,0 mg/m2 som intravenøs infusion over 30 minutter i 5 dage.
English: (95 % CI) Hazard ratio (95 % CI) N = total number of patients treated.
Danish: (95 % CI) Hazard ratio (95 % CI) N = antal behandlede patienter.
English: In clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 1.5 mg/dl.
Danish: Kombinationsterapi (cervixcancer): I kliniske studier med kombinationsbehandling med topotecan og cisplatin til behandling af cervixcancer blev behandlingen kun initieret for patienter med serumkreatinin ≤ 1,5 mg/dl.
English: Potactasol 4 mg powder for concentrate for solution for infusion EU/1/10/660/002
Danish: Potactasol 4 mg pulver til koncentrat til infusionsvæske, opløsning EU/1/10/660/002
English: Neutropenia: Severe (neutrophil count < 0.5 x 109/l) during course 1 in 55 % of patients, with duration ≥ seven days in 20 % and overall in 77 % of patients (39 % of courses).
Danish: Neutropeni: Alvorlig neutropeni (neutrofiltal < 0,5 x 109/l) under serie 1 hos 55 % af patienterne med en varighed ≥ syv dage hos 20 % og totalt set hos 77 % af patienterne (39 % af serierne).
English: When topotecan (0.75 mg/m2/day for 5 consecutive days) and cisplatin (60 mg/m2/day on day 1) were administered in 13 patients with ovarian cancer, a slight increase in AUC (12 %, n = 9) and Cmax (23 %, n = 11) was noted on day 5.
Danish: Ved administration af topotecan (0,75 mg/m2 legemsoverflade/dag i 5 sammenhængende dage) og cisplatin (60 mg/m2 legemsoverflade/dag på dag 1) til 13 patienter med ovariecancer, blev en svag stigning set i AUC(12 %, n = 9) og Cmax(23 %, n = 11) på dag 5.
English: Potactasol 1 mg powder for concentrate for solution for infusion EU/1/10/660/001
Danish: Potactasol 1 mg pulver til koncentrat til infusionsvæske, opløsning EU/1/10/660/001
English: Thrombocytopenia: Severe (platelets < 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Danish: Trombocytopeni: Alvorlig trombocytopeni (trombocyttal < 25 x 109/l) hos 25 % af patienterne (8 % af serierne), moderat (trombocyttal mellem 25,0 og 50,0 x 109/l) hos 25 % af patienterne (15 % af serierne).
English: The safety profile of topotecan when given in combination with cisplatin in the cervical cancer clinical studies is consistent with that seen with topotecan monotherapy.
Danish: Sikkerhedsprofilen fra kliniske studier med topotecan, givet i kombination med cisplatin mod cervixcancer, er i overensstemmelse med hvad der er set ved topotecan monoterapi.
English: Median survival in patients treated with oral topotecan plus BSC was 25.9 weeks (95 % CI 18.3, 31.6) compared to 13.9 weeks (95 % CI 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Danish: Medianoverlevelsen hos patienter behandlet med oral topotecan plus BSC var 25,9 uger (95 % CI 18,3; 31,6) sammenlignet med 13,9 uger (95 % CI 11,1; 18,6) for patienter, der modtog BSC alene (p = 0,0104).
English: Volume for 25 microgram/ml solution
Danish: Volumen for 25 migrogram/ml opløsning
English: If dose reduction is chosen for patients who experience severe neutropenia (neutrophil count < 0.5 x 109/l) for seven days or more, or severe neutropenia associated with fever or infection, or who have had treatment delayed due to neutropenia, the dose should be reduced by 0.25 mg/m2/day to 1.25 mg/m2/day (or subsequently down to 1.0 mg/m2/day if necessary).
Danish: Hvis dosisreduktion er valgt til patienter som oplever alvorlig neutropeni (neutrofiltal < 0,5 x 109/l) i syv dage eller mere, eller alvorlig neutropeni forbundet med feber eller infektion, eller hvis behandling er blevet udskudt på grund af neutropeni, skal dosis reduceres med 0,25 mg/m2/dag til 1,25 mg/m2 /dag (eller derefter om nødvendigt ned til 1,0 mg/m2 /dag).
English: The clear concentrate is pale yellow in colour and provides 1 mg per ml of topotecan, as Potactasol 1 mg contains a 10 % overage of fill.
Danish: Det klare koncentrat, hvis farve er lys gul, giver 1 mg topotecan pr. ml, da Potactasol 1 mg indeholder et overskud på 10 %.
English: The recommended dose of topotecan is 0.75 mg/m2/day administered as a 30-minute intravenous infusion on days 1, 2 and 3.
Danish: Den anbefalede dosis af topotecan er 0,75 mg/m2 legemsoverflade/dag administreret som en intravenøs infusion over 30 minutter på dag 1, 2 og 3.
English: In a comparative study of topotecan and paclitaxel in patients previously treated for ovarian carcinoma with platinum based chemotherapy (n = 112 and 114, respectively), the response rate (95 % CI) was 20.5 % (13 %, 28 %) versus 14 % (8 %, 20 %) and median time to progression 19 weeks versus 15 weeks (hazard ratio 0.7 [0.6, 1.0]), for topotecan and paclitaxel, respectively.
Danish: I et sammenlignende studie med topotecan og paclitaxel hos patienter tidligere behandlet for ovariecancer med platinbaseret kemoterapi (henholdsvis n = 112 og n = 114), var responsraten (95 % CI) 20,5 % (13 %, 28 %) versus 14 % (8 %, 20 %) og mediantiden til progression var 19 uger versus 15 uger (hazard ratio 0,7 [0,6; 1,0]) for henholdsvis topotecan og paclitaxel.
English: Cervical cancer The usual dose is 0.75 mg per m2 of body surface area once daily for 3 days.
Danish: Livmoderhalskræft Den sædvanlige dosis er 0,75 mg/m2 af kroppens overfladeareal pr. dag i 3 dage.
English: - Itching (pruritus).
Danish: − Amning (se pkt.
English: Vials may or may not be sheathed in a protective sleeve.
Danish: Hvert hætteglas kan være beklædt med et beskyttelsesskjold.
English: Initial dose The recommended dose of topotecan is 1.5 mg/m2 body surface area per day administered by intravenous infusion over 30 minutes daily for five consecutive days with a three week interval between the start of each course.
Danish: Første dosis Den anbefalede dosis af topotecan er 1,5 mg/m2 legemsoverflade pr. dag administreret som intravenøs infusion over 30 minutter hver dag fem dage i træk, med et interval på tre uger mellem begyndelsen af hver serie.
English: febrile neutropenia neutropenia (see Gastrointestinal disorders below) thrombocytopenia anaemia leucopenia
Danish: Meget almindelig: febril neutropeni neutropeni (se mave-tarm-kanalen nedenfor) trombocytopeni anæmi leukopeni
English: Median (95 % CI) Hazard ratio (95 % CI) Log rank p-value
Danish: Hazard ratio (95 % CI) Log rank p-værdi
English: mucosal inflammation
Danish: slimhindeinflammation
English: Patients without prior cisplatin chemoradiotherapy Cisplatin
Danish: Patienter uden forudgående cisplatin kemo/stråleterapi cisplatin topotecan/cisplatin
English: If dose reduction is chosen for patients who experience severe neutropenia (neutrophil count < 0.5 x 109/l) for seven days or more, or severe neutropenia associated with fever or infection or who have had treatment delayed due to neutropenia, the dose should be reduced by 20 % to 0.60 mg/m2/day for subsequent courses (or subsequently down to 0.45 mg/m2/day if necessary).
Danish: Ved dosisreduktion hos patienter, som oplever alvorlig neutropeni (neutrofiltal <0,5 x 109/l) i syv dage eller mere, eller alvorlig neutropeni forbundet med feber eller infektion, eller hvis behandlingen er blevet udskudt på grund af neutropeni, bør dosis reduceres med 20 % til 0,60 mg/m2/dag i de efterfølgende serier (eller derefter om nødvendigt ned til 0,45 mg/m2/dag).
English: For cervical cancer, it will be used together with another anticancer medicines containing cisplatin.
Danish: Ved behandling af livmoderhalskræft gives Potactasol sammen med et andet lægemiddel mod cancer, der indeholder cisplatin.
English: − Staff should be trained to reconstitute and dilute the the medicinal product.
Danish: − Personale skal oplæres i rekonstitution og fortynding af medikamentet.
English: Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of ≥ 1.5 x 109/l, a platelet count of ≥ 100 x 109/l and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary).
Danish: Før administration af den første serie med topotecan skal patienten have et neutrofiltal på ≥ 1,5 x 109/l og et trombocyttal på ≥ 100 x 109/l og et hæmoglobinniveau på ≥ 9g/dl (om nødvendigt efter transfusion) ved baseline.
English: Before infusion, Potactasol powder for concentrate for solution for infusion must be reconstituted with an appropriate volume of water for injections, as follows: - Potactasol 1 mg with 1.1 ml water for injections (as it contains 10 % overage of fill) - Potactasol 4 mg with 4 ml water for injections Reconstitution will result in a concentrate containing 1 mg topotecan per ml.
Danish: Potactasol pulver til koncentrat for infusionsvæske, skal før infusion rekonstitueres med en passende mængde vand til injektioner, som følger: - Potactasol 1 mg med 1.1 ml vand til injektioner (da det indeholder 10 % overskud) - Potactasol 4 mg med 4 ml vand til injektioner
English: The volume of reconstituted concentrate corresponding to the calculated individual dose should be further diluted with either sodium chloride 9 mg/ml (0.9 %) or 5 % w/v glucose, to give a final concentration of between 25 and 50 microgram per ml in the solution for infusion, for example:
Danish: Volumen af den rekonstituerede koncentrat svarer til den beregnede individuelle dosis og skal fortyndes yderligere med enten natriumchlorid 9 mg/ml (0,9 %) eller 5 % w/v glucose, til en endelig koncentration mellem 25 og 50 mikrogram pr. ml til opløsning for infusion, f.eks.:
English: What Potactasol is and what it is used for What you need to know before you use Potactasol How to use Potactasol
Danish: Virkning og anvendelse Det skal du vide, før du får Potactasol Sådan får du Potactasol Bivirkninger